Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-22T18:31:16.612Z Has data issue: false hasContentIssue false
  • English
  • Français

Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences

Published online by Cambridge University Press:  11 April 2011

Giovanni Santone ,
Gianmatteo Ricchi ,
David Rocchetti ,
Stefania Tofani  and
Cesario Bellantuono
Giovanni Santone*
Affiliation:
Psychiatric Unit, Department of Neuroscience, Polytechnic University of Marche, and United Hospitals of Ancona, Ancona (Italy)
Gianmatteo Ricchi
Affiliation:
Psychiatric Unit, Department of Neuroscience, Polytechnic University of Marche, and United Hospitals of Ancona, Ancona (Italy)
David Rocchetti
Affiliation:
Psychiatric Unit, Department of Neuroscience, Polytechnic University of Marche, and United Hospitals of Ancona, Ancona (Italy)
Stefania Tofani
Affiliation:
Psychiatric Unit, Department of Neuroscience, Polytechnic University of Marche, and United Hospitals of Ancona, Ancona (Italy)
Cesario Bellantuono
Affiliation:
Psychiatric Unit, Department of Neuroscience, Polytechnic University of Marche, and United Hospitals of Ancona, Ancona (Italy)
*
Address for correspondence: Dr G. Santone, Psychiatric Unit, United Hospitals of Ancona, Via Conca, 60020 Ancona (Italy). Fax: +39-071-596.3540 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

Aim – To review studies conducted to establish the risk of spontaneous abortion (SA) in women exposed to anti-depressant drugs (ADs) during early pregnancy. Methods – By using different search terms, PubMed, Toxline, EMBASE, PsychINFO, and the Cochrane library databases were searched from January 1980 to March 2008, to identify studies assessing the risk of SA in women exposed to different classes of ADs during the first trimester of pregnancy. Results – Ten studies over 21 identified were selected for the analysis. All were performed prospectively and included as control group unexposed women, or exposed to non-teratogenic drugs or to placebo. In seven studies a depressive episode was specified as the reason for which the drug was prescribed, while the time of exposure was in nine. Conclusions – Only three studies over ten selected reported a significant association between an increased rate of SAs and early pregnancy exposure to some ADs. Many methodological flaws in the study design were found in all studies considered. Given this background and a lack of strong evidence on this issue, further prospective and better designed studies are needed to assess the risk of SA in pregnant women exposed to ADs against the risk of an untreated maternal depression.

Declaration of Interest: None.

Keywords

antidepressant drugspregnancyspontaneous abortion
Type
Original Articles
Information
Epidemiology and Psychiatric Sciences , Volume 18 , Issue 3 , September 2009 , pp. 240 - 247
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Alwan, S., Reefhuis, J., Rasmussen, S.A., Olney, R.S. & Friedman, J.M. for the National Birth Defects Prevention Studies. (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New England Journal of Medicine 356, 2684–2692.CrossRefGoogle ScholarPubMed
American College of Obstetricians and Gynecologists. (2008). ACOG Practice Bulletin Number 92, April 2008. Obstetrics & Gynecology 4, 1001–1020.Google Scholar
Beck, C.T., Records, S. & Rice, M. (2006). Further development of the Post-partum Depression Predictors Inventory-Revised. Journal of Obstetric, Gynecologic & Neonatal Nursing 35, 735–745.CrossRefGoogle ScholarPubMed
Bellantuono, C., Migliarese, G. & Gentile, S. (2007). Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Human Psychopharmacology 22, 121–128.CrossRefGoogle ScholarPubMed
Bennett, H.A., Einarson, A., Taddio, A., Koren, G. & Einarson, T. (2004). Prevalence of depression during pregnancy: systematic review. Obstetrics & Gynecology 103, 698–709.CrossRefGoogle ScholarPubMed
Bonari, L., Pinto, N., Ahn, E., Einarson, A., Steiner, M. & Koren, G. (2004). Perinatal risk of untreated depression during pregnancy. Canadian Journal of Psychiatry 49, 726–735.CrossRefGoogle ScholarPubMed
Bonari, L., Koren, G., Einarson, T.R., Jasper, J.D., Taddio, A. & Einarson, A. (2005). Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Archives of Women’s Mental Health 8, 214–220.CrossRefGoogle ScholarPubMed
Boucher, N., Bairam, A. & Beaulac-Baillargeon, L. (2008). A new look at the neonate's clinical presentation after in utero exposure to antide-pressants in late pregnancy. Journal of Clinical Psychopharmacology 28, 334–339.CrossRefGoogle Scholar
Campagne, D.M. (2007). Fact: antidepressant and anxiolytics are not safe during pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology 135, 145–148.CrossRefGoogle Scholar
Chambers, C.D., Johnson, K.A., Dick, L.M., Felix, R.J. & Jones, K.L. (1996). Birth outcomes in pregnant women taking fluoxetine. New England Journal of Medicine 335, 1010–1015.CrossRefGoogle ScholarPubMed
Chun-Fai-Chan, B., Koren, G., Fayez, I., Kaira, S., Voyer-Lavigne, S., Boshier, A., Shakir, S. & Einarson, A. (2005). Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. American Journal of Obstetrics & Gynecology 192, 932–936.CrossRefGoogle ScholarPubMed
Cipriani, A., Nosè, M. & Barbui, C. (2007). What is a risk ratio? Epidemiologia e Psichiatria Sociale 16, 20–21.CrossRefGoogle ScholarPubMed
Cohen, L.S., Altshuler, L.L., Harlow, B.L., Nonacs, R., Newport, D.J., Viguera, A.C., Suri, R., Burt, V.K., Hendrick, V., Reminik, A.M., Loughead, A., Vitonis, A.S. & Stowe, Z.N. (2006). Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. Journal of the American Medical Association 295, 499–507.CrossRefGoogle ScholarPubMed
De Las Cuevas, C., Alvarez de La Rosa, M., Troyano, J.M. & Sanz, E.J. (2007). Are psychotropics drugs used in pregnancy? Pharmacoepidemiology and Drug Safety 16, 1018–1023.CrossRefGoogle ScholarPubMed
Dennis, C.L., Ross, L.E. & Grigoriadis, S. (2007). Psychosocial and psychological interventions for treating antenatal depression. Cochrane Database of Systematic Reviews 3, CD006309.Google Scholar
Diav-Citrin, O., Shechtman, S. & Weinbaum, D. (2002). Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort. Teratology 65, 298.Google Scholar
Djulus, J., Koren, G., Einarson, T.R., Wilton, L., Shakir, S., Diav-Citrin, O., Kennedy, D., Voyer-Lavigne, S., De Santis, M. & Einarson, A. (2006). Exposure to mirtazapine during pregnancy. A prospective and comparative study of birth outcomes. Journal of Clinical Psychiatry 67, 1280–1284.CrossRefGoogle ScholarPubMed
Edwards, G.J., Inman, W.H., Wilton, L. & Pearce, G.L. (1994). Prescription-event monitoring of 10401 patients treated with flu-voxamine. British Journal of Psychiatry 164, 387–395.CrossRefGoogle Scholar
Einarson, A. (2005). The safety of psychotropic drugs during pregnancy: a review. Medscape General Medicine 7, 3. Retrieved April 2, 2008, from http://medscape.com.Google ScholarPubMed
Einarson, A., Fatoye, B., Sarkar, M., Voyer-Lavigne, S., Brochu, J., Chambers, C., Mastroiacovo, P., Addis, A., Matsui, D., Schuler, L., Einarson, T.R. & Koren, G. (2001a). Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. American Journal of Psychiatry 158, 1728–1730.CrossRefGoogle ScholarPubMed
Einarson, A., Selby, P. & Koren, G. (2001b). Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. Journal of Psychiatry and Neuroscience 26, 44–48.Google ScholarPubMed
Einarson, A., Bonari, L., Voyer-Lavigne, S., Addis, A., Matsui, D., Johnoson, Y. & Koren, G. (2003). A multicentre prospective controlled study to determine the safety of trazodone and nefa-zodone used during pregnancy. Candian Journal of Psychiatry 48, 106–110.CrossRefGoogle ScholarPubMed
Einarson, A., Pistelli, A., De Santis, M., Malm, H., Paulus, W.D., Panchaud, A., Kennedy, D., Einarson, T.R. & Koren, G. (2008). Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. American Journal of Psychiatry 165, 749–752.CrossRefGoogle ScholarPubMed
Ericson, A., Kallen, B. & Wiholom, B.E. (1999). Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology 55, 503–508.CrossRefGoogle ScholarPubMed
Garcia-Enguidanos, A., Vaero, J., Luna, S. & Dominguez-Rojas, V. (2002). Risk factors in miscarriage: a review. European Journal of Obstetrics & Gynecology and Reproductive Biology 102, 111–119.CrossRefGoogle ScholarPubMed
Gavin, N.I., Gaynes, B.N., Lohr, K.N., Meltzer-Brody, S., Gartlehner, G. & Swinson, T. (2005). Perinatal depression a systematic review of prevalence and incidence. Obstetrics & Gynecology 106, 1071–1083.CrossRefGoogle ScholarPubMed
Gentile, S. (2005). SSRIs in pregnancy and lactation. Focus on neurode-velopmental outcome. CNS Drug Safety 28, 137–152.CrossRefGoogle Scholar
Gentile, S. (2007). Serotonin reuptake inhibitor-induced perinatal complications. Pediatric Drugs 9, 97–106.CrossRefGoogle ScholarPubMed
Gentile, S. & Bellantuono, C. (2009). SSRI_Exposure during early pregnancy and the risk of fetal major malformations: focus on paroxe-tine. Journal of Clinical Psychiatry 70, 414–422.CrossRefGoogle Scholar
Goldstein, D.J., Corbin, L.A. & Sundell, K.L. (1997). Effects of firsttrimester fluoxetine exposure on the newborn. Obstetrics & Gynecology 89, 713–718.CrossRefGoogle ScholarPubMed
Hemels, M.E.H., Einarson, A., Koren, G., Lanctôt, K.L. & Einarson, T.R. (2005). Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Annals of Pharmacotherapy 39, 803–809.CrossRefGoogle ScholarPubMed
Kulin, A.N., Pastuszak, A., Sage, S.R., Schick-Boschetto, B., Spivey, G., Feldkamp, M., Ormod, K., Matsui, D., Stein-Schechman, A.K., Cook, L., Brochu, J., Rieder, M. & Koren, G. (1998). Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. Journal of the American Medical Association 279, 609–611.CrossRefGoogle ScholarPubMed
Louik, C., Lin, A.E., Werler, M.M., Hernández-Díaz, S. & Mitchell, A.A. (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New England Journal of Medicine 356, 2675–2683.CrossRefGoogle ScholarPubMed
Maconochie, L., Doyle, P., Prior., & Simmons, R. (2007). Risk factors for first trimester miscarriage – results from a UK-population-based case-control-study. British Journal of Obstetrics and Gynaecolgy 114, 170–186.CrossRefGoogle ScholarPubMed
Malm, H., Klaukka, T. & Neuvonen, P.J. (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics & Gynecology 106, 1289–1296.CrossRefGoogle ScholarPubMed
Mc Elhatton, P.R., Garbis, H.M., Elefant, E., Vial, T., Bellemin, B., Mastroiacovo, P., Arnon, J., Rodriguez-Pinilla, E., Schaefer, C., Pexieder, T., Merlob, P. & Dal Verme, S. (1996). Outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressant. A collaborative study of European Network of Teratology Information and Service (ENTIS). Reproductive Toxicology 10, 285–294.CrossRefGoogle ScholarPubMed
National Institute for Health and Clinical Excellence. (2007). Antenatal and Postnatal Mental Health. Clinical Management and Service Guidance. NICE Clinical Guideline 45. National Institute for Health and Clinical Excellence: London.Google Scholar
Nonacs, R. & Cohen, L.S. (2003). Assessment and treatment of depression during pregnancy: an update. Psychiatric Clinics of North America 26, 547–562.CrossRefGoogle ScholarPubMed
Nulman, I., Rovet, J., Stewart, D.E., Wolpin, J., Gardner, H.A., Theis, J.G.W., Kulin, N. & Koren, G. (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. New England Journal of Medicine 336, 258–262.CrossRefGoogle ScholarPubMed
Osborn, J.F., Cattaruzza, M.S. & Spinelli, A. (2002). Risk of spontaneous abortion in Italy, 1978–1995, and the effect of maternal age, gravidity, marital status, and education. American Journal of Epidemiology 151, 98–105.CrossRefGoogle Scholar
Pastuszak, A., Schick-Boschetto, B., Zuber, C., Feldkamp, M., Pinelli, M., Sihn, S., Donnenfeld, A., McCormack, M., Leen-Mitchell, M. & Woodland, C. (1993). Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). Journal of the American Medical Association 269, 2246–2249.CrossRefGoogle ScholarPubMed
Rahimi, R., Nikfar, S. & Abdollahi, M. (2006). Pregnancy outcome following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reproductive Toxicology 22, 571–575.CrossRefGoogle ScholarPubMed
Ramos, E., St-André, M., Ray, E., Oraichi, D. & Bérard, A. (2008). Duration of antidepressant use during pregnancy and risk of major congenital malformations. British Journal of Psychiatry 192, 344–350.CrossRefGoogle ScholarPubMed
Simon, G.E., Cunningham, M.L. & Davis, R.L. (2002). Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry 159, 2055–2061.CrossRefGoogle ScholarPubMed
Sivojelezova, A., Shuhaiber, S., Sarkissian, L., Einarson, A. & Koren, G. (2005). Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and foetal outcome. American Journal of Obstetrics & Gynecology 193, 2004–2009.CrossRefGoogle Scholar
Spinelli, M.G. & Endicott, J. (2003). Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. American Journal of Psychiatry 160, 555–562.CrossRefGoogle ScholarPubMed
Suri, R., Altshuler, L., Hendrick, V., Rasgon, N., Lee, E. & Mintz, J. (2004). The impact of depression and fluoxetine treatment on obstetrical outcome. Archives of Women’s Mental Health 7, 193–200.CrossRefGoogle ScholarPubMed
Suri, R., Altshuler, L., Hellemann, G., Burt, V.K., Aquino, A. & Mintz, J. (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. American Journal of Psychiatry 164, 1206–1213.CrossRefGoogle ScholarPubMed
Yaris, F., Kadioglu, M., Kesim, M., Ulku, C., Yaris, E., Kalyoncu, N.I. & Unsal, M. (2004). Newer antidepressants in pregnancy: prospective outcome of a case series. Reproductive Toxicology 19, 235–238.CrossRefGoogle ScholarPubMed
Yaris, F., Ulku, C., Kesim, M., Kadioglu, M., Unsal, M., Fevzi, Dikici M., Kalyoncu, N.I. & Yaris, E. (2005). Psychotropic drugs in pregnancy: a case-control study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 333–338.CrossRefGoogle ScholarPubMed
Wen, S.W., Yang, Q., Garner, P., Fraser, W., Olatunbosun, O., Nimrod, C. & Walker, M. (2006). Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. American Journal of Obstetrics & Gynecology 194, 961–966.CrossRefGoogle ScholarPubMed
Wisner, K.L., Zarin, D.A., Holmboe, E.S., Appelbaum, P.S., Gelenberg, A.J., Leonard, H.L. & Frank, E. (2000). Risk-benefit decision making for treatment of depression during pregnancy. American Journal of Psychiatry 157, 1933–1940.CrossRefGoogle ScholarPubMed